Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic diseases, the analyst tells investors in a research note. The firm says the company’s lead drug Azelaprag has a differentiated mechanism of action as exercise mimetic for obesity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: